Margenza

Active Ingredient(s): Margetuximab-cmkb
FDA Approved: * December 16, 2020
Pharm Company: * MACROGENICS INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Margenza Overview

Margetuximab, sold under the brand name Margenza, is a chimeric IgG monoclonal antibody medication against HER2 used for the treatment of cancer.[3][4] The most common adverse drug reactions in combination with chemotherapy are fatigue/asthenia, nausea, diarrhea, vomiting, constipation, headache, pyrexia, alopecia, abdominal pain, peripheral neuropathy, arthralgia/myalgia, cough, decreased appetite, dyspnea, infusion-related reactions, palmar-plantar erythrodys...

Read more Margenza Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Margetuximab

Recent Margenza Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Other drugs which contain Margetuximab-cmkb or a similar ingredient: (1 result)

• MARGETUXIMAB